العلاج السابق — لم يتحقق الهدف
استُخدم مثبط المناعة الجهازي من الخط الثالث — الأزاثيوبرين أو السيكلوسبورين — إلا أنه لم يحقق الهدف المطلوب: زيادة الحد الأدنى للاستجابة الحمامية في اختبارات الضوء بعد 3 أشهر. يمثل هذا البروتوكول الخطوة المتخذة عند عدم بلوغ هذا الحد.
References
DOI: 10.1034/j.1600-0781.2003.00048.x
The dose of hydroxychloroquine used was 400 mg daily for the first month and 200 mg thereafter for a total of 12 weeks.
When taken at a dose of 2–3 g daily before sun exposure, 60% patients reported complete abolition of symptoms despite continued sun exposure, while 26% reported no benefit.
In uncontrolled studies, 10 g mixed o-3 PUFAs (MaxEPAs, Seven Seas, Hull, UK), taken as five capsules twice daily day for 3 months, significantly increased the MED to UVB, and significantly increased the threshold for UVA-provocation of rash.
In a case series of 25 patients with 'PLE', 88% good to excellent lesion healing was reported with thalidomide.
A randomized, double-blind controlled study involving 30 PLE patients showed that three topical antioxidant mixtures (comprising a-glycosylrutin, tocopherol acetate and ferulic acid), significantly reduced the development and severity of PLE induced experimentally.
A small preliminary study involving nine patients suggested that its intramuscular, but not oral, administration significantly increased the provocation threshold of PLE to UVA.
View source ↗